When was GenrAb founded?

GenrAb was founded in 2022 and raised its 1st funding round 3 years after it was founded.

Where is GenrAb located?

GenrAb is headquartered in Dallas, United States.

Is GenrAb a funded company?

GenrAb is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Apr 22, 2025.

When was the latest funding round of GenrAb?

GenrAb's latest funding was a $***** Seed round on Apr 22, 2025, with participation from 4 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.57B in funding in 2026 to date.

Where does GenrAb rank among its competitors?

GenrAb ranks 196th amongst 457 active competitors, of which 159 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of GenrAb?

GenrAb's top competitors include Denali Therapeutics, Regenxbio and AviadoBio. Among them, Alchemab secured the most recent funding round in July, 2026.

GenrAb - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of neuroprotective monoclonal antibodies for treating neurological disorders. It focuses on developing therapies that protect and treat patients with neurological diseases. The company's proprietary Antibody Gene Signature (AGS) technology identifies potentially therapeutic fully-human mAbs to treat neurological disorders. These antibodies leverage naturally created neuroprotective mechanisms found in individuals experiencing neurodegeneration. The company aims to prevent disease progression and provide neuroprotection.

Key Metrics

Founded Year

2022

Location

Dallas, United States

Stage

Seed

Total Funding

$5.6M in 1 round

Latest Funding Round

Seed, Apr 22, 2025, $*****

Investors

Actium & 3 more

Ranked

196^th among 457 active competitors

Similar Companies

Denali Therapeutics & 567 more

View GenrAb's full profile

GenrAb has raised a total funding of $5.6M over 1 round. Its latest funding round was a Seed round on Apr 22, 2025 for $*****. 4 investors participated in its latest round. GenrAb has 4 institutional investors.

Here is the list of recent funding rounds of GenrAb:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 22, 2025	8716553	Seed	2822696	4996839	9065640	3545558

Access funding benchmarks and valuations. Sign up today!

View details of GenrAb's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GenrAb include Denali Therapeutics, Regenxbio and AviadoBio. Here is the list of Top 10 competitors of GenrAb, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	74/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	68/100
3rd	AviadoBio 2019, London (United Kingdom), Series A	Developer of gene therapies for neurodegenerative disorders	$80M	Monograph, New Enterprise Associates & 9 others	67/100
4th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	66/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
6th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	64/100
7th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	64/100
8th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	63/100
10th	Amylyx Pharmaceuticals 2013, Cambridge (United States), Public	Developer of small-molecule therapeutics for neurodegenerative diseases	$172M	Morningside, Viking Global Investors & 16 others	63/100
196th	GenrAb 2022, Dallas (United States), Seed	Developer of neuroprotective monoclonal antibodies for treating neurological disorders	$5.6M	Research Bridge Partners, Salem Partners & 2 others	34/100